Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Alpelisib (Primary) ; Enzalutamide (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 10 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.